CRBN and neuroblastoma: The PROTAC molecule dBET57, which targets BRD4, degrades the BET protein family and MYCN through CRBN-mediated ubiquitination, effectively inhibiting the MYCN SE regulatory genes TBX3 and ZMYND8 in the MNA-NB xenograft model and showing therapeutic potential (Jia et al., 2022).